Research Article

High Blood Pressure Effects on the Blood to Cerebrospinal Fluid Barrier and Cerebrospinal Fluid Protein Composition: A Two-Dimensional Electrophoresis Study in Spontaneously Hypertensive Rats

Ibrahim González-Marrero,1 Leandro Castañeyra-Ruiz,1,2 Juan M. González-Toledo,1 Agustín Castañeyra-Ruiz,3 Hector de Paz-Carmona,3 Rafael Castro,4 Juan R. Hernandez-Fernaud,3 Agustín Castañeyra-Perdomo,1 and Emilia M. Carmona-Calero 1

1 Departamento de Anatomía, Facultad de Medicina, Universidad de La Laguna, Ofra s/n, 38071 La Laguna, Tenerife, Spain
2 Departamento de Farmacología, Facultad de Medicina, Universidad de La Laguna, Ofra s/n, 38071 La Laguna, Tenerife, Spain
3 Instituto de Investigación y Ciencias de Puerto del Rosario, c/Tenerife n 35, 35600 Puerto del Rosario, Fuerteventura, Spain
4 Departamento de Fisiología, Facultad de Medicina, Universidad de La Laguna, Ofra s/n, 38071 La Laguna, Tenerife, Spain

Correspondence should be addressed to Agustín Castañeyra-Perdomo; acastane@ull.es

Received 4 September 2012; Revised 25 October 2012; Accepted 13 November 2012

Academic Editor: Claudio Borghi

The aim of the present work is to analyze the cerebrospinal fluid proteomic profile, trying to find possible biomarkers of the effects of hypertension of the blood to CSF barrier disruption in the brain and their participation in the cholesterol and β-amyloid metabolism and inflammatory processes. Cerebrospinal fluid (CSF) is a system linked to the brain and its composition can be altered not only by encephalic disorder, but also by systemic diseases such as arterial hypertension, which produces alterations in the choroid plexus and cerebrospinal fluid protein composition. 2D gel electrophoresis in cerebrospinal fluid extracted from the cistern magna before sacrifice of hypertensive and control rats was performed. The results showed different proteomic profiles between SHR and WKY, that α-1-antitrypsin, apolipoprotein A1, albumin, immunoglobulin G, vitamin D binding protein, haptoglobin and α-1-macroglobulin were found to be up-regulated in SHR, and apolipoprotein E, transthyretin, α-2-HS-glycoprotein, transferrin, α-1β-glycoprotein, kininogen and carbonic anhydrase II were down-regulated in SHR. The conclusion made here is that hypertension in SHR produces important variations in cerebrospinal fluid proteins that could be due to a choroid plexus dysfunction and this fact supports the close connection between hypertension and blood to cerebrospinal fluid barrier disruption.

1. Introduction

Cerebrospinal fluid is a functional system closely connected to the brain, and changes or variations in the CSF may mean an alteration in the brain expressed by encephalic disorders. However, the composition of CSF may also be altered by systemic diseases, such as arterial hypertension, and cerebral ventricular dilatation, changes in CSF protein, and variations of the choroid plexus and other circumventricular organs (CVO) have been described in spontaneously hypertensive rats (SHR) [1–5]. Therefore, SHR develop hydrocephalus and experimental studies explain that hydrocephalus induces alterations in CSF since there are disturbances, in the hydrocephalic brain, of oxidative metabolism and neurotransmission and perhaps damage to periventricular cells, particularly when intracranial pressure is elevated [6]. The sharp increase in systemic blood pressure only causes an acute increase in CSF pressure in normotensive animals and not in
hypertensive patients [6]. The CSF pressure of SHR showed greater protection to the acute effects of phenylephrine than in control Wistar-Kyoto (WKY) rats, but a permeability increase of the blood to cerebrospinal fluid barrier to sucrose in rats with chronic hypertension was detected [7]. The blood–brain barrier (BBB) was found to be resistant to the passage of sucrose and lanthanum in both SHR and WKY rats, indicating that BBB integrity was maintained, however, there is a reduced brain uptake of sucrose in SHR compared to WKY, which is consistent with decreased brain capillary density and reduction of cerebral blood flow (CBF) in SHR compared to WKY [7]. Furthermore, in a previous study, increases of transthyretin (TTR) monomer and S-100 β in blood have been described in SHR which means a disruption of the brain barriers [8].

The brain is one of the first target organs of high blood pressure, which is the main modifiable risk factor for stroke. Hypertension causes a progressive increase in cerebral blood flow in the blood vessels of the brain that perform complex and dynamic relationships between blood pressure and brain function. High blood pressure can accelerate atherosclerotic changes and affect cerebral autoregulation [9]. On the other hand, epidemiological studies link cardiovascular risk factors such as hypertension and high plasma cholesterol to dementia. The modulation of the degradation of amyloid precursor protein by the administration of cholesterol in cell cultures and animal models of beta-amyloid overproduction has been described [10] and a connection between inflammation, hypertension and beta-amyloid accumulation has also been reported [11].

Subsequently, as mentioned above, a previous work has reported that high blood pressure produces alterations in the circumventricular organs (CVO), ventricular dilation, variations in the protein composition of the CSF, an increase in the inflammatory process in the brain, and alterations of beta-amyloid metabolism. The aim of the present work is to analyze the protein composition of the CSF of the SHR and its relationship with the integrity of the blood to CSF barrier.

2. Materials and Methods

2.1. Animals. Thirty-six-month-old rats divided into two groups were used: a control group of 15 Wistar-Kyoto (WKY) and a hypertensive group of 15 spontaneously hypertensive rats (SHR) from Charles River Laboratories España S.A. (Barcelona, Spain). The animals were maintained at a constant temperature of 21 ± 2°C and 55 ± 8% relative humidity on a normal 12–12-hour light-dark cycle. The systolic blood pressure (SBP) of SHR and WKY rats at 6 months of age was measured indirectly using the tail-cuff method in conscious rats.

2.2. Cerebrospinal Fluid Samples. Animals were anesthetized with chloral hydrate (400 mg/kg) and placed in a stereotaxic frame. CSF was extracted from the cistern magna of the SHR and WKY rats. The CSF was centrifuged (4,000 g for 4 min) to remove blood contamination from the puncture point. Cleared CSF was stored at −80°C.

2.3. Immunohistochemistry. The brains of four rats from each group were fixed with Bouin fixative, embedded in paraffin, and cut in four (A, B, C, and D) parallel series of section at a thickness of 10 μm. The brain areas containing the choroid plexus (CP) of the A series were stained with hematoxylin-eosin (H-E). The sections of the other series (B, C, and D) containing the CP, after deparaffinization and rehydration, tissues were treated with hot (85°C) 10 mM citrate buffer, pH 6, for 20 min. Sections were washed with distilled water and quenched with 3% hydrogen peroxide for 10 min at room temperature to eliminate endogenous peroxidase activity. After washing in 0.05 M Tris-buffered saline (TBS) pH 7.6, the sections were incubated with anti-rat IgG 1 : 200 (Sigma) for two hours, then the sections were washed in TBS and stained using 3,3-diaminobenzidine (DAKO).

The immunohistochemical slides were converted into digital images by using a LEICA DMRB photomicroscope with a LEICA DC 300 F camera (Germany). Image analysis was completed in Image J (v. 1.43 u, NIH, Bethesda, MD, USA). The “Mean Gray Value” was measured from the selected areas for all stained tissues. This value gives the average stain intensity in grayscale units for all threshold pixels. The immunohistochemistry statistical study was conducted using the IBM SPSS statistic 19 software (one-way ANOVA).

2.4. 2D Gel Electrophoresis in CSF. CSFs from SHR and WKY rats were pooled and samples were solubilized in buffer with 8 M urea, 4% CHAPS, 40 mM Tris, 65 mM DTE, 0.05% SDS, and 2% ampholytes. Isoelectrofocusing was performed using glass capillary tubes (1.5 mm id and 12 cm length) and capillary tubes were filled with solution containing 3% acrylamide, 7 M urea, 0.6% Triton X-100, 0.75% ampholytes pH 5–8, 0.22% ampholytes pH 3–10, and 0.22% ampholytes pH 7–9, 0.045% TEMED, and 0.08% APS were used to separate proteins in the 4–8 pH range. Samples containing approximately 100 μg total proteins were applied to the base end of the tube gel and were resolved in cathode and anode buffers of 20 mM NaOH and 8.7 mM H3PO4, respectively. IEF was carried out in steps of 1 hr at 100 and then 300 V, followed by 17.5 hr at 1000 V and 30 minutes at 2000 V. The capillaries were then equilibrated for 15 minutes in reducing buffer containing 50 mM Tris.HCl [pH 8.8], 30% glycerol, 6 M urea, 2% SDS, and 1% DTT, followed by a blocking step for another 15 minutes in a similar buffer containing 2.5% iodoacetamide instead of DTT. The capillary gels were then transferred to the top of an 18 × 18 cm, 1.5-mm-thick, 10% polyacrylamide gel (SDS-PAGE) and embedded in 0.5% low-melting agarose containing a trace of bromophenol blue. SDS-PAGE was run at 15°C, initially at 20 mA for 15 min and then at 50 mA per gel until the blue front reached the bottom. Molecular mass markers (Sigma) were loaded onto the second dimension for external calibration. The protein spots were visualized in preparative gels by staining with the colloidal Coomassie stain. Gels were scanned using a UMAX scanner (Amersham Biosciences) and the images were analyzed with Melanie version 5.0 software (GeneBio, Geneva, Switzerland), which included spot detection, quantification, normalization, and data analysis. Matching corresponding
spots across different gels was performed by comparative analysis of protein spots, and each of the matched protein spots was checked manually. The intensity volumes of the individual spots were normalized to the total intensity volume of all the spots present in each gel and were subjected to Kolmogorov statistical analysis to compare the normalized intensity volumes of the individual spots from the controls to those of the hypertensive group. Only differentially expressed proteins were excised and subsequently identified by a mass spectrometer (MS).

2.5. MALDI-TOF-MS. Protein spots were manually excised from stained gels and the tryptic in-gel digestion and desalting steps were performed using 96-well ZipPlates (Millipore, Bedford, MA, USA) according to the manufacturer’s instructions. The resulting peptides were mixed with 1 μL α-cyano-4-hydroxycinnamic acid (CHCA; 1 mg/mL) and spotted onto Anchorchip plates as described by the manufacturer (Bruker-Daltonics, Bremen, Germany). Peptide mass fingerprint spectra were measured on an Autoflex MALDI-TOF (Bruker-Daltonics) in a positive ion reflection mode and spectra in the 900-3, 200 Da range were recorded. The PMF data were submitted to the MASCOT search engine for protein identification using the Mascot database. The search parameters were set according to the following criteria: rattus for taxonomy, carbamidomethyl (C) for fixed modifications, oxidation (M) for variable modifications, and ±100 ppm for peptide ion mass tolerance.

3. Results

3.1. Hematoxylin-Eosin. The WKY rats (Figure 1) show the typical structure of the choroid plexus, that is, the cubical morphology of the epithelial choroid plexus cells, little stroma, and small blood vessels. SHR show that the flattening of the choroid plexus epithelial cells and the stroma is greater in size, where the distance between the epithelium and choroidal vessels increased. The blood vessel diameter is also greater in SHR when compared to the controls. The morphology of CP becomes irregular, since continuity is lost in some areas between epithelial cells. Furthermore, the morphology of the nucleus has changed from circular to ellipsoid (Figure 1).

3.2. Immunohistochemistry. The IgG labeling in WKY rats was very low or almost undetectable in most of the choroid plexus tissues, and only a little amount of IgG located around blood vessels can be observed (Figure 2). By contrast, the IgG immunoreactive was clearly observed in the CP of SHR; the IgG was more intensive and distributed in a large number of
cerebral vessels, in the stroma and basolateral membrane of the CP (Figure 2).

3.3. 2D Electrophoresis. The protein changes found were classified in three groups: group 1 correlated with the blood to CSF barrier (BCSFB), group 2 correlated with β-amyloid and cholesterol metabolism, and group 3 correlated with acute phase inflammatory process. The results showed different proteomic profiles between SHR and WKY; α-1-antitrypsin, apolipoprotein A1, albumin, immunoglobulin G, vitamin D binding protein, haptoglobin, and α-1-macroglobulin were upregulated in SHR and apolipoprotein E, transthyretin, α-2-HS-glycoprotein, transferrin, α-1β-glycoprotein, kininogen,
and carbonic anhydrase II were downregulated in SHR (Figures 3, 4 and 5 and Table 1).

4. Discussion

The 2D gel electrophoresis of the CSF showed many protein variations in the CSF of SHR rats which are expressed by a different proteomic profile when comparing control and hypertensive rats, where some proteins are differentially expressed in the CSF of SHR compared to WKY. Six-month-old rats were chosen because, according to Zicha and Kuneš [13], there are the major differences between the blood pressure of SHR and WKY at this age. Among these variations, the most noteworthy changes found in the three groups are as follows.

4.1. Blood-to-CSF Barrier Related Proteins. Some authors have reported that chronic hypertension in SHR may cause more pronounced defects in the integrity of the blood-to-CSF barrier than the blood-brain barrier (BBB) [7, 14]. Transthyretin is found in CP and is secreted in the CSF [7, 14]. Low levels of TTR in SHR compared to WKY were found in this work; these differences in the blood-to-CSF barrier may explain the decrease of TTR in the CSF of SHR, allowing its passage from the CSF to the vascular space [7, 8, 14]. Therefore, this protein can be used to analyze the integrity of the BCSFB. Alternatively, the carbonic-anhydrase II (CA II) is abundantly expressed in the brain; it has been found by others in the CP and leaking into the CSF [15, 16]. The CA II level during CP development may be involved in early CSF secretion and the movement of water into the cerebral ventricles [17], secretion, and movement of water that appear to be altered in SHR since CA II is clearly lower in the results presented here. IgG immunoreactive was clearly greater in all of the CP structural components of SHR; furthermore, IgG, albumin and haptoglobin are also stronger in the CSF of the SHR, which may be caused by damage to the BSLCR allowing their passage into the CSF [17–19]. In the proteomic
Table 1: List of proteins detected in CSF that are altered, high or low in SHR compared to WKY using 2D electrophoresis and identified by mass spectrometry as described in Section 2.

| ID | Protein                                      | NCBI nr | Theoretical MW (Da)/pI | Matched peptide | Sequence coverage (%) | Mascot score | Missed cleavage | Fold SHR expression |
|----|----------------------------------------------|---------|------------------------|------------------|-----------------------|--------------|------------------|---------------------|
| 1a | α-1-Antitrypsin                              | gi:112889 | 46.278/5.70            | 8                | 22                    | 82           | 1                | +1.75               |
| 1b | α-1-Antitrypsin                              | gi:112889 | 46.278/5.70            | 9                | 27                    | 81           | 1                | +2.95               |
| 1c | α-1-Antitrypsin                              | gi:112889 | 46.278/5.70            | 9                | 25                    | 83           | 1                | +2.60               |
| 2a | Apolipoprotein A1                            | gi:178775 | 28.070/5.27            | *Identification from Finehout et al., 2004 [12] | +5.37       |                |                   |
| 2b | Apolipoprotein A1                            | gi:178775 | 28.070/5.27            | *Identification from Finehout et al., 2004 [12] | +5.79       |                |                   |
| 3  | Apolipoprotein E                             | gi:1703338 | 35.788/5.23            | 9                | 27                    | 78           | 0                | −1.92               |
| 4a | Transhyretin                                 | gi:136467 | 15.824/5.77            | 5                | 43                    | 97           | 1                | −2.86               |
| 4b | Transhyretin                                 | gi:136467 | 15.824/5.77            | 7                | 59                    | 85           | 1                | −3.54               |
| 5  | Albumin                                     | gi:5391508 | 70.682/6.09            | 13               | 25                    | 190          | 1                | +1.41               |
| 6  | α-2-HS Glycoprotein                          | gi:231468 | 38.757/6.05            | 5                | 21                    | 85           | 0                | −1.32               |
| 7  | Transferrin                                  | gi:122066515 | 78.512/7.14      | 12               | 22                    | 169          | 1                | −2.04               |
| 8  | α-1-β Glycoprotein                           | gi:23503038 | 51.870/5.51            | *Identification from Finehout et al., 2004 [12] | −3.26       |                |                   |
| 9  | Ig gamma-2A chain C region                   | gi:121052 | 35.677/7.72            | 3                | 11                    | 59           | 1                | +1.79               |
| 10 | Kininogen                                    | gi:60293582 | 48.828/6.08            | 6                | 16                    | 63           | 1                | −1.52               |
| 11a| Vitamin D Binding Protein                    | gi:139643 | 55.106/5.65            | 14               | 34                    | 166          | 1                | +2.21               |
| 11b| Vitamin D Binding Protein                    | gi:139643 | 55.106/5.65            | 8                | 21                    | 55           | 1                | +1.24               |
| 12a| Haptoglobin                                  | gi:5908182 | 39.052/6.10            | 8                | 22                    | 89           | 1                | +2.67               |
| 12b| Haptoglobin                                  | gi:5908182 | 39.052/6.10            | 5                | 11                    | 63           | 0                | +3.42               |
| 13 | Carbonic anhydrase II                        | gi:9506445 | 29.698/6.9             | 6                | 33                    | 121          | 0                | −2.83               |
| 14 | Alpha-1-macroglobulin                        | gi:205384 | 168.422/6.46           | 10               | 8                     | 71           | 1                | +1.83               |
study of the CSF of the SHR and WKY, albumin, IgG, and the two detected isoforms of haptoglobin were higher in SHR with respect to WKY rats (Table 1). These data support the idea that the hypertension produces an increase in some proteins derived from blood plasma due to a disruption of the BSLCR.

4.2. β-Amyloid and Cholesterol Metabolism. Apolipoprotein E (Apo E) is a molecule of the apolipoprotein family which is the main component of quilomicrones. Apo A1 is the most abundant apolipoprotein in plasma, almost all of which is present in HDL (cholesterol) and is about 90% and 65% of the protein fraction in HDL2 and HDL3 (cholesterol), respectively. Apo E and Apo A1 together with the TTR and vitamin D binding proteins are clearly implicated in the metabolism of β-amyloid and cholesterol [20]. α-1-macroglobulins are a family of glycoproteins that inhibit all four types of proteinases by a trapping mechanism [21]. Furthermore, the reaction of lecithin cholesterol acyltransferase (LCAT) with high density lipoprotein (HDL) is very important in reverse cholesterol transport [22, 23]. A decrease of Apo E in CSF of the SHR compared with WKY was found in the results here, but the proteins binding vitamin D, Apo A1, and α-1-macroglobulin are higher in the hypertensive group, which could explain the relationship between hypertension, inflammation, and amyloid pathology [11, 24].

4.3. Acute Phase Inflammatory Process. The CP is the main source of transferrin in the brain where it binds to the iron coming from the bloodstream [25]. Neuron survival requires iron, which is predominantly delivered by transferrin. The concentration of transferrin in CSF reflects brain iron availability and can serve as a biomarker in different diseases [25] such as arterial hypertension, which has effects on the secretory capacity of the CP, resulting in lower transferrin levels in the CSF of the SHR with respect to WKY.

The α-2-Heremans-Schmid glycoprotein (α-2-HS), also known as fetuin-A, is present in the serum being synthesized.
Figure 5: Differences in optic density between differential proteins of CSF from WKY and SHR. Abbreviations: A1AT: α-1-antitrypsin, Apo A1: apolipoprotein A1, Apo E: apolipoprotein E, TTR: transthyretin, ALB: albumin, HS Gly: α-2-HS-glycoprotein, TF: transferrin, B-Gly: α-1-β glycoprotein, IgG: IgG gamma-2A chain C region, KNG: kininogen, VDBP: vitamin D binding protein, HP: haptoglobin, CA: carbonic anhydrase, and MG: α-1 macroglobulin.

by hepatocytes, but the α-2-HS is also synthesized in the CP and secreted into the CSF, where its principal function is to inhibit pathologic calcifications, since it is capable of forming complexes with calcium and phosphorus [26]. The α-2-HS are lower in the CSF of the SHR (Table 1); this decrease could be due to damage in the CP secretions. By contrast, the vitamin D binding protein is higher in the CSF of the SHR. The association between the vitamin D binding protein and hypertension is not clear, but it is thought that this protein, because it is linked to the inflammatory process, could be higher since high blood pressure produces an increase of the inflammatory process as a consequence of the brain damage [27, 28]. Three isoforms of α-1-antitrypsin are also higher in the CSF of the SHR when compared to the CSF of the control; such an increase could be due to the three isoforms being implicated in the inflammatory processes which are present in degenerative diseases and in SHR [28–31]. Kininogens are other proteins that are also implicated in inflammation [32], and in the present study kininogens were found to be lower in the CSF of the SHR than in the CSF of the control groups. The study here reports many variations of the proteins participating in inflammatory processes present in SHR; therefore, these results agree with the work of other authors [27, 28] who have reported that hypertension in SHR rats produces several glycoprotein alterations. Differences in other proteins such as α-1-β glycoprotein were found, which have not been directly related to the development of hypertension, but which have been proposed as biomarkers of diseases with inflammatory processes [29, 33].

This paper reports that the effects of high blood pressure in the brain can be observed in the CSF composition, where two different proteomic profiles were found between SHR and WKY. Among the diverse proteins found, the most noteworthy are α-1 antitrypsin, apolipoprotein A1, apolipoprotein E, transthyretin, albumin, α-2-HS glycoprotein, transferrin, α-1-β glycoprotein, IgG, kininogen, vitamin D binding protein, and haptoglobin. Therefore, one could conclude that the high blood pressure in SHR produces CSF variations of proteins that are connected with the blood-to-CSF barrier integrity, cholesterol metabolism, and inflammatory processes, which could be a cause or consequence of choroid plexus alterations and the blood-to-CSF barrier disruption.

Acknowledgment

This work was supported by the Fundación Canaria Instituto de Investigación y Ciencias de Puerto del Rosario (INIPRO) projects no. 01/10 and no. 02/10.

References

[1] W. A. Bonadio, L. Stancu, R. Bruce, D. Barry, and D. Smith, “Reference values of normal cerebrospinal fluid composition in infants ages 0 to 8 weeks,” *Pediatric Infectious Disease Journal*, vol. 11, no. 7, pp. 589–591, 1992.

[2] C. E. Johanson, J. A. Duncan, P. M. Kline, T. Brinker, E. G. Stopa, and G. D. Silverberg, “Multiplicity of cerebrospinal fluid functions: new challenges in health and disease,” *Cerebrospinal Fluid Research*, vol. 5, article 10, 2008.

[3] E. M. Carmona-Calero, H. Perez-Gonzalez, I. Martinez-Peña y Valenzuela et al., “Effect of the arterial hypertension and captopril treatment on the angiotensin II content in the subfornical
organ. A study in SHR rats,” Histology and Histopathology, vol. 20, no. 1, pp. 135–138, 2005.

[4] E. M. Carmona-Calero, I. González-Marrero, M. Castañeyra-Martin et al., “Hypertension effects on p73 expression in the rat circumventricular organs and cerebrospinal fluid,” World Journal of Neuroscience, vol. 2, no. 2, pp. 68–73, 2012.

[5] I. González-Marrero, E. M. Carmona-Calero, P. Fernández-Rodriguez et al., “Expression of certain proteins in the subfornical organ and cerebrospinal fluid of spontaneously hypertensive rats,” Histology and Histopathology, vol. 22, no. 12, pp. 1371–1378, 2007.

[6] M. R. Del Bigio, “Hydrocephalus-induced changes in the composition of cerebrospinal fluid,” Neurosurgery, vol. 25, no. 3, pp. 416–423, 1989.

[7] H. Al-Sarraf, F. Ghaaedi, and Z. Redzic, “Time course of hypertensive opening of the blood-brain and blood-CSF barriers in spontaneously hypertensive rats,” Journal of Vascular Research, vol. 44, no. 2, pp. 99–109, 2007.

[8] I. Gonzalez-Marrero, L. Castañeyra-Ruiz, J. M. Gonzalez-Toledo et al., “High blood pressure effects on the brain barriers and choroid plexus secretion,” Neuroscience & Medicine, vol. 3, no. 1, pp. 60–64, 2012.

[9] F. Veglio, C. Paglieri, F. Rabbia, D. Bisbocci, M. Bergui, I. Gonzalez-Marrero, L. Castañeyra-Ruiz, J. M. Gonzalez-Toledo et al., “Highblood pressure effectsonthebrainbarriers and choroid plexus secretion,” Histochemistry and Cytochemistry, vol. 22, no. 4, pp. 283–292, 2006.

[10] J. Poirier, “Apolipoprotein E and cholesterol metabolism in the pathogenesis and treatment of Alzheimer’s disease,” Trends in Molecular Medicine, vol. 9, no. 3, pp. 94–100, 2003.

[11] D. Carnevale, G. Mascio, M. A. Ajmone-Cat et al., “Role of neuroinflammation in hypertension-induced brain amyloid pathology,” Neurobiology of Aging, vol. 33, no. 1, pp. 205.e19–205.e29, 2012.

[12] E. J. Finehout, Z. Franck, and K. H. Lee, “Towards two-dimensional electrophoresis mapping of the cerebrospinal fluid proteome from a single individual,” Electrophoresis, vol. 25, no. 15, pp. 2564–2575, 2004.

[13] J. Zicha and J. Kuneš, “Ontogenetic aspects of hypertension development: analysis in the rat,” Physiological Reviews, vol. 79, no. 4, pp. 1227–1282, 1999.

[14] H. Al-Sarraf and L. Philip, “Effect of hypertension on the integrity of blood brain and blood CSF barriers, cerebral blood flow and CSF secretion in the rat,” Brain Research, vol. 975, no. 1-2, pp. 179–183, 2003.

[15] T. Kumpulainen and L. K. Korhonen, “Immunohistochemical localization of carbonic anhydrase isoenzyme C in the central and peripheral nervous system of the mouse,” The Journal of Histochemistry and Cytochemistry, vol. 30, no. 4, pp. 283–292, 1982.

[16] A. K. Parkkila, S. Parkkila, W. Serlo, M. Reunanen, T. Vierjoki, and H. Rajeniemi, “A competitive dual-label time-resolved immunofluorometric assay for simultaneous detection of carbonic anhydrase I and II in cerebrospinal fluid,” Clinica Chimica Acta, vol. 230, no. 1, pp. 81–89, 1994.

[17] P. Johansson, K. Dziegielew ska, and N. Saunders, “Low levels of Na, K-ATPase and carbonic anhydrase II during choroid plexus development suggest limited involvement in early CSF secretion,” Neuroscience Letters, vol. 442, no. 1, pp. 77–80, 2008.

[18] M. J. Garton, G. Keir, M. Vijaya Lakshmi, and E. J. Thompson, “Age-related changes in cerebrospinal fluid protein concentrations,” Journal of the Neurological Sciences, vol. 104, no. 1, pp. 74–80, 1991.

[19] H. Reiber, “Proteins in cerebrospinal fluid and blood: barriers, CSF flow rate and source-related dynamics,” Restorative Neurology and Neuroscience, vol. 21, no. 3–4, pp. 79–96, 2003.

[20] C. Kirsch, G. P. Eckert, A. R. Koudinov, and W. E. Müller, “Brain cholesterol, statins and Alzheimer’s disease,” Pharmacochemistry, vol. 36, supplement 2, pp. S113–S119, 2003.

[21] L. Sottrup-Jensen, “α-Macroglobulins: structure, shape, and mechanism of proteinase complex formation,” The Journal of Biological Chemistry, vol. 264, no. 20, pp. 11539–11542, 1989.

[22] S. Swarnakar, J. Beers, D. K. Strickland, S. Azhar, and D. L. Williams, “The apolipoprotein E-dependent low density lipoprotein cholesteryl ester selective uptake pathway in murine adrenocortical cells involves chondroitin sulfate proteoglycans and an α2-macroglobulin receptor,” The Journal of Biological Chemistry, vol. 276, no. 24, pp. 21121–21128, 2001.

[23] L. Krimbou, M. Marcil, J. Davignon, and J. Genest, “Interaction of Lecithin-Cholesterol Acyltransferase (LCAT) α2-macroglobulin complex with low density Lipoprotein Receptor-related Protein (LRP): evidence for an α2-macroglobulin/LRP receptor-mediated system participating in LCAT clearance,” The Journal of Biological Chemistry, vol. 276, no. 35, pp. 33241–33248, 2001.

[24] M. T. Gentile, R. Poulet, A. D. Pardo et al., “β-Amyloid deposition in brain is enhanced in mouse models of arterial hypertension,” Neurobiology of Aging, vol. 30, no. 2, pp. 222–228, 2009.

[25] D. F. Leitner and J. R. Connor, “Functional roles of transferrin in the brain,” Biochimica Et Biophysica Acta, vol. 1820, no. 3, pp. 393–402, 2012.

[26] W. Jahnen-Dechent, C. Schäfer, M. Ketteler, and M. D. McKee, “Mineral chaperones: a role for fetuin-A and osteopontin in the inhibition and regression of pathologic calcification,” Journal of Molecular Medicine, vol. 86, no. 4, pp. 379–389, 2008.

[27] J. Benicky, E. Sánchez-Lemus, M. Honda et al., “Angiotensin II AT1 receptor blockade ameliorates brain inflammation,” Neuropsychopharmacology, vol. 36, no. 4, pp. 857–870, 2011.

[28] L. Sun, Y. H. Gao, D. K. Tian et al., “Inflammation of different tissues in spontaneously hypertensive rats,” Sheng Li Xue Bao, vol. 58, no. 4, pp. 318–323, 2006.

[29] P. Davidsson and M. Bjögren, “Proteome studies of CSF in AD patients,” Mechanisms of Ageing and Development, vol. 127, no. 2, pp. 133–137, 2006.

[30] J. Zhang, C. D. Keene, C. Pan, K. S. Montine, and T. J. Montine, “Proteomics of human neurodegenerative diseases,” Journal of Neuropathology and Experimental Neurology, vol. 67, no. 10, pp. 923–932, 2008.

[31] M. A. Korolainen, T. A. Nyman, P. Nyyssönen, E. S. Hartikainen, and T. Pirtilä, “Multiplexed proteomic analysis of oxidation and concentrations of cerebrospinal fluid proteins in Alzheimer disease,” Clinical Chemistry, vol. 53, no. 4, pp. 657–665, 2007.

[32] F. Abdì, J. F. Quinn, J. Jankovic et al., “Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders,” Journal of Alzheimer’s Disease, vol. 9, no. 3, pp. 293–348, 2006.

[33] M. Puchades, S. F. Hansson, C. L. Nilsson, N. Andreassen, K. Blennow, and P. Davidsson, “Proteomic studies of potential cerebrospinal fluid protein markers for Alzheimer’s disease,” Molecular Brain Research, vol. 118, no. 1-2, pp. 140–146, 2003.